One would predict that CAR T cells manufactured in the presence of Interleukin-15 will exhibit a significantly increased release of effector cytokines (e.g., IFN-γ, TNF-α, IL-2) upon antigen stimulation compared to CAR T cells manufactured without Interleukin-15.